(67 days)
Not Found
No
The device description and performance studies focus on the physical characteristics, safety features, and material properties of insulin pen needles, with no mention of AI or ML technologies.
No.
The device is a needle for injection of insulin, which is a drug delivery device, not a therapeutic device itself.
No
The device, an insulin pen needle, is used for the subcutaneous injection of insulin, which is a treatment delivery function, not a diagnostic one.
No
The device description clearly indicates the device is a physical needle and not software.
No, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostics are medical devices used to perform tests on samples taken from the human body (like blood, urine, or tissue) to provide information about a person's health. These tests are performed outside the body.
- Device Function: The description clearly states the device is an "Insulin Pen Needle" intended for "subcutaneous injection of insulin." This means it's used to deliver a substance into the body, not to test samples taken from the body.
- Intended Use: The intended use is for injecting insulin, which is a therapeutic action, not a diagnostic one.
- Device Description: The description focuses on the physical characteristics of the needle and its safety features for injection, not on any analytical or testing capabilities.
The device described is a medical device used for drug delivery, specifically insulin injection. It falls under a different regulatory category than IVDs.
N/A
Intended Use / Indications for Use
The Insulin Pen Needle (Ordinary Type) is intended for use with pen injector devices for the subcutaneous injection of insulin.
The Insulin Pen Needle (Safety Type) is sterile, single-use safety needle intended for use with pen injector devices for the injection of insulin.
Product codes (comma separated list FDA assigned to the subject device)
FMI
Device Description
The proposed devices, Insulin Pen Needle (Ordinary Type) and Insulin Pen Needle (Safety Type) are single use device, which is designed for used with a pen injector for the subcutaneous injection of insulin. For the safety type, it is designed with a sharp injury prevention feature to minimize the risk from accidental needles sticks. The proposed device is available in 29G, 30G, 31G, 32G and 33G five different specifications with the needle length available in 4mm, 5mm, 6mm, 10mm and 12mm for Insulin Pen Needle (Ordinary Type) and 4mm, 5mm, and 8mm for Insulin Pen Needle (Safety Type). The product is for single use and provided sterile (Irradiation). The shelf-life of the product is five-years.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
In hospital or in the home environment.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Non clinical tests were conducted to verify that the proposed device met all design specifications and that the subject device is Substantially Equivalent (SE) to the predicate device. The test results demonstrated that the proposed device complies with the following standards:
- ISO 7864: 2016 Sterile hypodemic needles for single use
- ISO 9626: 2016 Stainless steel needle tubing for the manufacture of medical devices
- ISO 11608-2: 2012 Needle-based injection systems for medical use- Requirements and test methods- Part 2: Needles
- ISO 23908 :2011 Sharps injury protection - Requirements and test methods -Sharps protection features for single-use hypodermic needles, introducers for catheters and needles used for blood sampling
Biocompatibility testing was conducted in accordance with ISO 10993-1, including:
- Cytotoxicity
- Sensitization
- Irritation
- Acute Systemic Toxicity
- Material-Mediated Pyrogenicity
- Subacute Toxicity
- Hemocompatibility
Particulate matter testing was conducted in accordance with USP Particulate Matter in Injections and met the USP acceptance criteria.
Sterility, Shipping and Shelf-Life:
The Insulin Pen Needles were sterilized by irradiation to achieve a SAL of 10-6. The radiation source was Electron beam, and the radiation dose was 25kGy, which was established according to VDmax method per ISO11137-2. The sterilization was validated according to ISO 11137-2. The Insulin Pen Needles were evaluated for bacterial endotoxin utilizing the USP Limulus Amebocyte Lysate (LAL) method.
- Package integrity testing, after environmental conditioning and simulated transportation was conducted on the final, packaged, and sterile devices. All packaging deemed acceptable for protection of product and sterility maintenance.
- Sterile Barrier Packaging Testing performed on the proposed device:
- Seal strength ASTM F88/F88-15
- Dye penetration ASTM F1929-15
Shelf life of 5 years is validated using the FDA recognized standard ASTM F1980-16 Standard Guide for Accelerated Aging of Sterile Barrier Systems for Medical Devices.
Simulated Clinical Use:
A simulated clinical use study was performed on 600 device samples for the Insulin Pen Needle (Safety Type) according to FDA Guidance (Guidance for Industry and FDA Staff: Medical Device with Sharps Injury Prevention Feature) and ISO 23908:2011 to evaluate the safety mechanism of the proposed device. The results demonstrated that the proposed device met the pre-established criteria.
No clinical study is included in this submission.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 880.5570 Hypodermic single lumen needle.
(a)
Identification. A hypodermic single lumen needle is a device intended to inject fluids into, or withdraw fluids from, parts of the body below the surface of the skin. The device consists of a metal tube that is sharpened at one end and at the other end joined to a female connector (hub) designed to mate with a male connector (nozzle) of a piston syringe or an intravascular administration set.(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the FDA logo is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
Tianjin Huahong Technology Co., Ltd. Yuan Ying Quality Manager A01, Plant B, No. 278, Hangkong Road, Tianjin Pilot Free Trade Zone(Air Port Industrial Park) Tianiin. 300308 China
Re: K221176
Trade/Device Name: Insulin Pen Needle (Ordinary Type, Safety Type) Regulation Number: 21 CFR 880.5570 Regulation Name: Hypodermic Single Lumen Needle Regulatory Class: Class II Product Code: FMI Dated: June 16, 2022 Received: June 16, 2022
Dear Yuan Ying:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part
1
801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
For CAPT Alan M. Stevens Assistant Director DHT3C: Division of Drug Delivery and General Hospital Devices. and Human Factors OHT3: Office of GastroRenal, ObGyn, General Hospital and Urology Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
2
Indications for Use
Form Approved: OMB No. 0910-0120 Expiration Date: 06/30/2023 See PRA Statement below.
Submission Number (if known)
Device Name
Insulin Pen Needle (Ordinary Type, Safety Type)
Indications for Use (Describe)
The Insulin Pen Needle (Ordinary Type) is intended for use with pen injector devices for the subcutaneous injection of insulin.
The Insulin Pen Needle (Safety Type) is sterile, single-use safety needle intended for use with pen iniector devices for the injection of insulin.
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
[X] Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) Summary - K221176
l Submitter
Tianjin Huahong Technology Co., Ltd.
A01, Plant B, No.278, Hangkong Road, Tianjin Pilot Free Trade Zone (Air Port Industrial Park), 300308 Tianjin, China
Establishment Registration Number: 3009498536
Contact person: Ms. Ying Yuan Quality Manager Tel.: +86-18622179097 E-mail: ying.yuan@hh-technology.com
Preparation date: July 1, 2022
II Proposed Device
| Trade Name of Device: | Insulin Pen Needle (Ordinary Type, Safety Type) |
|---|---|
| Classification name: | Hypodermic, Single Lumen |
| Regulation Number: | 21 CFR 880.5570 |
| Regulatory Class: | Class II |
| Product code: | FMI |
| Review Panel | General Hospital |
III Predicate Devices
| 510(k) Number: | K181069 |
|---|---|
| Trade name: | Disposable Insulin Pen Needle |
| Classification: | Class II |
| Product Code: | FMI |
| Manufacturer | Zhejiang Kindly Medical Devices Co. Ltd |
| 510(k) Number: | K170988 |
| Trade name: | DropSafe Safety Pen Needle |
| Classification: | Class II |
| Product Code: | FMI |
| Manufacturer | HTL-Strefa S.A. |
4
IV Device description
The proposed devices, Insulin Pen Needle (Ordinary Type) and Insulin Pen Needle (Safety Type) are single use device, which is designed for used with a pen injector for the subcutaneous injection of insulin. For the safety type, it is designed with a sharp injury prevention feature to minimize the risk from accidental needles sticks. The proposed device is available in 29G, 30G, 31G, 32G and 33G five different specifications with the needle length available in 4mm, 5mm, 6mm, 10mm and 12mm for Insulin Pen Needle (Ordinary Type) and 4mm, 5mm, and 8mm for Insulin Pen Needle (Safety Type). The product is for single use and provided sterile (Irradiation). The shelf-life of the product is five-years.
V Indication for use
The Insulin Pen Needle (Ordinary Type) is intended for use with pen injector devices for the subcutaneous injection of insulin.
The Insulin Pen Needle (Safety Type) is sterile, single-use safety needle intended for use with pen injector devices for the injection of insulin.
| Table 1 General Comparison for Insulin Pen Needle (Ordinary Type) | ||
|---|---|---|
| ITEM | Proposed Device | |
| K202319 | Predicate Device 1 | |
| K181069 | ||
| Proprietary/ trade name | Insulin Pen Needle (Ordinary Type) | Disposable Insulin Pen Needle |
| Regulation No. | 880.5570 | 880.5570 |
| Product Code | FMI | FMI |
| Class | II | II |
| Intended Use | The Insulin Pen Needle (Ordinary Type) is intended for use with pen injector devices for the subcutaneous injection of insulin. | The Disposable Insulin Pen Needle is intended for use with pen injector devices for the subcutaneous injection of insulin. |
| Environment of use | In hospital or in the home environment. | In hospital or in the home environment. |
| Type-of-use | Disposable | Disposable |
| Configuration and materials of construction for all components | Needle Tube Stainless Steel | Needle Tube Stainless Steel |
| Needle Hub Polypropylene | Hub Polypropylene | |
| Outer Sheath Polypropylene | Cup Polyethylene | |
| Inner Sheath Polypropylene | Inner Sheath Polypropylene | |
| Sealed Paper | ||
| Paper | Sealed Paper | |
| Paper |
VI Comparison of technological characteristics with the predicate devices
5
| Operation Mode | For Manual Use Only | For Manual Use Only |
|---|---|---|
| Method | ||
| of | ||
| attachment to pen | ||
| injector | Through threaded connection | Through threaded connection |
| Table 2 Safety and Performance Comparison for Insulin Pen Needle (Ordinary Type) |
|---|
| Proposed Device | Predicate | |
|---|---|---|
| ITEM | K202319 | Device 1 |
| K181069 | ||
| Needle Gauge | 29G, 30G, 31G, 32G, 33G | 28G, 29G, 30G, |
| 31G, 32G, 33G | ||
| Needle Length | 4mm, 5mm, 6mm, 8mm, 10mm, 12mm | 4mm, 6mm, |
| 8mm, 12mm | ||
| Patient-contact materials | ||
| Needle Tube | Stainless Steel (SUS304) | Stainless Steel |
| Lubricant | MDX4-4159 | Unknown |
| adhesive | UV glue | Unknown |
| Bond between hub and | ||
| needle tube | Clause 4.4 of ISO 11608-2:2012; | |
| Clause 4.12 of ISO 7864:2016 | Clause 4.4 of ISO 11608-2:2012; | |
| Clause 4.12 of ISO 7864:2016 | ||
| Design specification of the | ||
| inner sheath (dimensions, | ||
| color, materials and | ||
| strength) | 14.35.85.8mm; | |
| Transparent color; Polypropylene; | ||
| Tensile stress at yield>20MPa; Flexural | ||
| modulus: >800MPa; Charpy Notched | ||
| Impact Strength (23°C ) >2.8kJ/m². | Unknown | |
| Design specification of the | ||
| outer sheath (dimensions, | ||
| color, materials and | ||
| strength) | 30.313.413.4mm; | |
| Transparent color; Polypropylene; | ||
| Tensile stress at yield>20MPa; Flexural | ||
| modulus: >800MPa; Charpy Notched | ||
| Impact Strength (23°C ) >2.8kJ/m². | Unknown | |
| Needle tip configuration | Conform with ISO 7864 standards | Conform with |
| ISO 7864 | ||
| standards | ||
| Cytotoxicity | No Cytoxicity | No Cytoxicity |
| Intracutaneous reactivity | No Irritation to Skin | No Irritation to Skin |
| Skin Sensitization | No skin sensitization | No skin sensitization |
| Acute Systemic Toxicity | No Systemic Toxicity | No Systemic Toxicity |
| Pyrogen | No pyrogen | No pyrogen |
6
| Hemolysis | No hemolysis | |
|---|---|---|
| Subacute Systemic Toxicity | No Subacute Systemic Toxicity | Unknown |
| Method | Irradiation Sterilized | EO Sterilized |
| SAL | 10-6 | 10-6 |
| Endotoxin Limit | 20 EU per device | 20 EU per device |
| Shelf life | 5 years | Unknown |
| Label/ Labeling | Complied with 21 CFR part 801 | Complied with 21 CFR part 801 |
Table 3 General Comparison for Insulin Pen Needle (Safety Type)
| ITEM | Proposed Device | Predicate Device 2 |
|---|---|---|
| K202319 | K170988 | |
| Regulation No. | 880.5570 | 880.5570 |
| Product Code | FMI | FMI |
| Class | II | II |
| Intended Use | The Insulin Pen Needle (Safety Type) is sterile, single-use safety needle intended for use with pen injector devices for the injection of insulin. | The DropSafe Safety Pen Needles are sterile, single-use safety needles intended for use with pen injector devices for the injection of drugs. |
| Environment of use | In hospital or in the home environment. | In hospital or in the home environment. |
| Proprietary/ trade name | Insulin Pen Needle (Safety Type) | DropSafe Safety Pen Needles |
| Type-of-use | Disposable | Disposable |
| Configuration and materials of construction for all components | Needle Tube Stainless Steel (SUS304) | Cannula Medical grade stainless steel |
| Needle Hub Polypropylene | Hub Plastic resin | |
| Outer Sheath Polypropylene | Primary container Plastic resin | |
| Inner Sheath Polypropylene | Slider Unknown | |
| Sealed Paper Paper | Seal Unknown | |
| Spring Stainless Steel (SUS304) | Spring- operated Stainless steel wire | |
| Upper Cover Polypropylene | Needle shield Plastic resin |
7
| Operation Mode | For Manual Use Only | For Manual Use Only | |
|---|---|---|---|
| Method of | |||
| attachment to pen | |||
| injector | Threaded connection method. | Threaded connection method. | |
| Safety Feature | Prevent from needlestick | Prevent from needlestick | |
| Method of | |||
| activation | Trigger shield | Trigger shield |
| ITEM | Proposed Device
K202319 | Predicate Device 2
K170988 |
|-----------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------|
| Needle Gauge | 29G, 30G, 31G, 32G, 33G | 31G |
| Needle Length | 4mm, 5mm, 6mm, 8mm | 6mm and 8mm |
| Patient-contact material | | |
| Needle Tube | Stainless Steel (SUS304) | Medical grade stainless steel |
| Lubricant | MDX4-4159 | Unknown |
| adhesive | UV glue | Unknown |
| Bond between hub and
needle tube | Drawing force≥22N (29G) ;
Drawing force≥ 11N (30G-33G);Clause 4.4 of ISO
11608-2:2012;
Clause 4.12 of ISO 7864:2016 | Clause 4.4 of ISO 11608-2:2012;
Clause 4.12 of ISO 7864:2016 |
| Design specification of the
inner sheath (dimensions,
color, materials and
strength) | 21.510.79.8mm;
Transparent color;
Polypropylene.
Tensile stress at
yield>20MPa; Flexural
modulus: >800MPa;
Charpy Notched Impact
Strength (23°C ) >2.8kJ/m² . | Unknown |
| Design specification of the
outer sheath (dimensions,
color, materials and
strength) | 43.818.618.6mm;
Transparent color;
Polypropylene.
Tensile stress at
yield>20MPa; Flexural
modulus: >800MPa;
Charpy Notched Impact
Strength (23°C ) >2.8kJ/m². | Unknown |
| Design specification of the
upper cover (dimensions, | 30.214.614.6mm;
White: | Unknown |
| color, materials and
strength) | Polypropylene.
Tensile stress at
yield>20MPa; Flexural
modulus: >800MPa;
Charpy Notched Impact
Strength (23°C) >2.8kJ/m². | |
| Needle tip configuration | Conform with ISO 7864 standards | Conform with ISO 7864 standards |
| Biocompatibility | | |
| Cytotoxicity | No Cytoxicity | |
| Intracutaneous reactivity | No Irritation to Skin | |
| Skin Sensitization | No skin sensitization | Conform with ISO 10993 standards |
| Acute Systemic Toxicity | No Systemic Toxicity | |
| Pyrogen | No pyrogen | |
| Hemolysis | No hemolysis | |
| Subacute Systemic Toxicity | No Subacute Systemic
Toxicity | Unknown |
| Sterilization | | |
| Method | Irradiation Sterilized | Irradiation Sterilized |
| SAL | 10-6 | 10-6 |
| Endotoxin Limit | 20 EU per device | 20 EU per device |
| Shelf life | 5 years | Unknown |
| Label/ Labeling | Complied with 21 CFR part 801 | Complied with 21 CFR part 801 |
Table 4 Safety and Performance Comparison for Insulin Pen Needle (Safety Type)
8
VII Compatible injectors
The Insulin Pen Needle can be used in combination with following pen injector available and cleared in the USA:
- Autopen ® K983974 Owen Mumford, Inc.
- Novopen Echo ® K162602 Novo Nordisk Inc.
- Humapen and Humapen Ergo K982842 Eli Lilly and Company -
- Humapen Luxura K142518 Eli Lilly and Company -
- -Humapen Memoir K053563 Eli Lilly and Company
VIII Non-Clinical Testing
Non clinical tests were conducted to verify that the proposed device met all design specifications and that the subject device is Substantially Equivalent (SE) to the predicate device. The test results demonstrated that the proposed device complies with the following standards:
Performance Testing:
9
-
ISO 7864: 2016 Sterile hypodemic needles for single use
-
ISO 9626: 2016 Stainless steel needle tubing for the manufacture of medical devices
-
ISO 11608-2: 2012 Needle-based injection systems for medical use- Requirements and test methods- Part 2: Needles
- ハ ISO 23908 :2011 Sharps injury protection - Requirements and test methods -Sharps protection features for single-use hypodermic needles, introducers for catheters and needles used for blood sampling
Biocompatibility Testing:
In accordance with ISO 10993-1, the Insulin Pen Needles are classified as: Externally communicating, indirect blood path with prolonged contact duration (>24 h to 30 d). The direct and indirect patient-contact component(s) along with the material(s) for the proposed devices are identified as follows:
| Components | Material | Contact Level | Contact Duration |
|---|---|---|---|
| Needle Tube | Stainless Steel | ||
| (SUS304) | Indirect, blood path | prolonged (>24hrs to 30 days) | |
| Adhesive | UV glue | Indirect, blood path | prolonged (>24hrs to 30 days) |
| Lubricant | MDX4-4159 | Indirect, blood path | prolonged (>24hrs to 30 days) |
| Needle hub | Polypropylene | Direct contact with intact skin | Limited (≤24 h) |
| Outer sheath | Polypropylene | Direct contact with intact skin | Limited (≤24 h) |
Table 5 Patient Contact Material Identification
The following testing was conducted:
- . Cytotoxicity
- . Sensitization
- Irritation ●
- . Acute Systemic Toxicity
- Material-Mediated Pyrogenicity .
- Subacute Toxicity .
- . Hemocompatibility
Particulate matter testing was conducted in accordance with USP Particulate Matter in Injections and met the USP acceptance criteria.
Sterility, Shipping and Shelf-Life
The Insulin Pen Needles were sterilized by irradiation to achieve a SAL of 10 °. The radiation source
10
was Electron beam, and the radiation dose was 25kGy, which was established according to VDmax method per ISO11137-2, Sterilization of healthcare products-Radiation establishing the sterilization dose. The sterilization was validated according to ISO 11137-2. The Insulin Pen Needles were evaluated for bacterial endotoxin utilizing the USP Limulus Amebocyte Lysate (LAL) method.
- . Package integrity testing, after environmental conditioning and simulated transportation was conducted on the final, packaged, and sterile devices. All packaging deemed acceptable for protection of product and sterility maintenance.
- Sterile Barrier Packaging Testing performed on the proposed device: .
- Seal strength ASTM F88/F88-15 o
- o Dye penetration ASTM F1929-15
Shelf life of 5 years is validated using the FDA recognized standard ASTM F1980-16 Standard Guide for Accelerated Aging of Sterile Barrier Systems for Medical Devices
Simulated Clinical Use
A simulated clinical use study was performed on 600 device samples for the Insulin Pen Needle (Safety Type) according to FDA Guidance (Guidance for Industry and FDA Staff: Medical Device with Sharps Injury Prevention Feature) and ISO 23908:2011 to evaluate the safety mechanism of the proposed device. The results demonstrated that the proposed device met the pre-established criteria.
VIII Clinical Testing
No clinical study is included in this submission.
IX Conclusion
The clinical and non-clinical performance testing demonstrate that the subject device is as safe and effective as the predicate. Therefore, the subject device is substantially equivalent to the predicate device.